Park Avenue Securities LLC Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Park Avenue Securities LLC boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 17.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,294 shares of the biopharmaceutical company’s stock after acquiring an additional 1,225 shares during the period. Park Avenue Securities LLC’s holdings in Halozyme Therapeutics were worth $337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Rise Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 1st quarter worth approximately $25,000. Principal Securities Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $34,000. First Horizon Advisors Inc. boosted its stake in Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares in the last quarter. Parkside Financial Bank & Trust acquired a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $64,000. Finally, Headlands Technologies LLC grew its holdings in shares of Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,613 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $803,876.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 40,000 shares of company stock valued at $1,858,100 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HALO shares. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $48.00 to $51.00 in a research report on Friday, June 7th. JMP Securities dropped their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, June 24th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Finally, Benchmark lifted their target price on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.25.

Get Our Latest Analysis on HALO

Halozyme Therapeutics Trading Up 1.4 %

Shares of Halozyme Therapeutics stock opened at $52.36 on Monday. The company has a fifty day simple moving average of $45.31 and a 200-day simple moving average of $40.45. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 0.53 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $53.00. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with's FREE daily email newsletter.